Lutetium-177 XT 117 - Sinotau Pharmaceuticals
Alternative Names: 177Lu-XT117 - Sinotau pharmaceuticals; [177Lu]Lu-XT117 - Sinotau pharmaceuticalsLatest Information Update: 02 Feb 2024
At a glance
- Originator Sinotau Pharmaceuticals
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 18 Jan 2024 Sinotau Pharmaceutical initiates a phase-I clinical trials in Solid tumours (Late-stage disease) in China (Parenteral) (NCT06211647)
- 09 Jan 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (Parenteral) (NCT06197139)